How does Perjeta work (mechanism of action)?
Perjeta (pertuzumab) is a monoclonal antibody designed to block a specific interaction on HER2 (ERBB2) receptors. It binds to the extracellular domain of HER2 at a site that prevents HER2 from pairing with other HER family receptors, especially HER3 (ERBB3). By blocking HER2/HER3 dimerization, Perjeta reduces downstream signaling that drives tumor growth and survival [1].
What signaling pathway does Perjeta affect downstream?
When HER2 pairs with HER3, it activates signaling cascades that promote cell proliferation and survival, including pathways commonly linked to PI3K/AKT activity. By blocking HER2-HER3 pairing, Perjeta suppresses these downstream growth and survival signals [1].
What’s the difference between Perjeta and Herceptin?
Both target HER2, but they bind different parts of the HER2 receptor. Perjeta binds HER2 in a way that blocks HER2/HER3 dimer formation, while Herceptin (trastuzumab) binds a different HER2 epitope. This difference matters because blocking dimerization can more directly interfere with HER2-driven signaling through HER3, which is a key partner receptor [1].
Why is Perjeta typically used with trastuzumab and chemotherapy?
Perjeta’s dual-receptor approach is commonly paired with trastuzumab and chemotherapy to improve treatment effect. The combination uses different mechanisms directed at the same HER2 pathway: Perjeta blocks HER2/HER3 signaling via dimerization inhibition, while trastuzumab provides additional HER2-targeted activity, and chemotherapy attacks dividing cells through cytotoxic mechanisms [1].
Where does Perjeta fit in breast cancer treatment biology?
Perjeta is used in HER2-positive cancers because tumors with elevated HER2 signaling depend heavily on HER2-containing receptor complexes to sustain growth. By interrupting receptor pairing that supports that signaling, Perjeta helps reduce the tumor’s ability to maintain oncogenic signaling [1].
Source
[1] Perjeta (pertuzumab) prescribing information and mechanism description (via DrugPatentWatch): https://www.drugpatentwatch.com/p/perjeta-pertuzumab/